Historical review of carbamazepine for the treatment of bipolar disorder

Pharmacotherapy

Volumn 27, Issue 1, 2007, Pages 68-88

  Stoner, Steven C ^a,b   Nelson, Leigh Anne ^a,c   Lea, Jessica W ^a,d   Marken, Patricia A ^a   Sommi, Roger W ^a,c   Dahmen, Megan M ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Northwest Missouri Psychiatric Rehabilitation Center   (United States)

^c Western Missouri Mental Health Center   (United States)

^d Truman Behavioral Health   (United States)

Author keywords

Acute mania; Bipolar disorder; Carbamazepine; Extended release formulation; Immediate release formulation; Maintenance phase; Mixed episodes

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; CARBAMAZEPINE; CIMETIDINE; CITALOPRAM; CLARITHROMYCIN; CLONAZEPAM; DANAZOL; DEXTROPROPOXYPHENE; DILTIAZEM; DULOXETINE; ERYTHROMYCIN; FELBAMATE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LORATADINE; MICROTROL; MIRTAZAPINE; NEFAZODONE; PHENYTOIN; PRIMIDONE; PROTEINASE INHIBITOR; QUETIAPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

AGRANULOCYTOSIS; APLASTIC ANEMIA; BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE EXACERBATION; DIZZINESS; DRUG CROSS REACTIVITY; DRUG FORMULATION; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MANIA; META ANALYSIS; MIXED MANIA AND DEPRESSION; RAPID CYCLING BIPOLAR DISORDER; RASH; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CONTROLLED CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; LACTATION; PREGNANCY;

EID: 33846083794     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.1.68     Document Type: Review

References (87)

1. Fankhauser MP, Freeman MP. Bipolar disorder. In: DiPiro JT, Talbert RL, eds. Pharmacotherapy: a pathophysiologic approach, 6th ed. New York: McGraw-Hill Companies, Inc., 2005:1257-84.
2. Hirscheld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9.
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8-19.
4. Keck PE, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001;85:645-61.
5. Duffy A, Grof P, Robertson C, Aida M. The implications of genetic studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61:630-7.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000.
7. American Psychiatric Association. Practice guideline for the treatment of subjects with bipolar disorder (revision). Am J Psychiatry 2002;159(4 suppl):1-50.
8. Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. The expert consensus, guideline series: treatment of bipolar disorder 2004. Postgrad Med Special Report 2004;(December):1-120.
9. Suppes T, Dennehy EB, Swann AC, et al. Report on the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J Clin psychiatry 2002;63:288-99.
10. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004;161:3-18.
11. Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1999;60(suppl 5):5-13.
12. Ahmad A, Garnett WR. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. Curr Med Res Opin 2005;21:1363-8.
13. Amann B, Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 2005;46(suppl 4):26-30.
14. Stahl SM. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? J Clin Psychiatry 2004;65:149-50.
15. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004;9:734-55.
16. Yoshimura R, Nakamura J, Eto S, Ueda N. Possible relationships between plasma carbamazepine 10-11-epoxide levels and antimanic efficacy and side effects in patients with schizoaffective disorder. Hum Psychopharmacol Clin Exp 2000;15:237-40.
17. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5:3-14.
18. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
19. Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 2000;20(8 pt 2):S139-51.
20. Jensen PK, Moller A, Gram L, Jensen NO, Dam M. Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurol Scand 1990;82:135-7.
21. Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 2004;109:374-7.
22. Novartis Pharmaceuticals. Tegretol XR (carbamazepine extended-release tablet) package insert. East Hanover, NJ; 2003.
23. Shire Pharmaceuticals. Equetro (carbamazepine extended-release capsule) package insert. Wayne, PA; 2004.
24. McLean A, Browne S, Zhang Y, Slaughter E, Halstenson C, Couch R. The influence of food on the bioavailability of a twice-daily controlled-release carbamazepine formulation. J Clin Pharmacol 2001;41:183-6.
25. Stevens RE, Limsakun T, Evans G, Mason DH. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). J Pharm Sci 1998;87:1531-4.
26. Konsil J, Mason D, Stevens R. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended-release formulations. J Pharm Pharmaceut Sci 2002;5:169-75.
27. Garnett WR, Levy B, McLean AM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998;39:274-9.
28. Weisler RH. Carbamazepine extended-release capsules for the treatment of bipolar I disorder. Therapy 2005;2:533-44.
29. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro. I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Disp 2002;30:1170-9.
30. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics 2005;46:464-94.
31. Staines AG, Coughtrie MWH, Burchell B. N-glucuronidation of carbamazepine in human tissue is mediated by UGT2B7. J Pharm Exp Ther 2004;311:1131-7.
32. Harrison TS, Keating GM. Extended-release carbamazepine capsules in bipolar I disorder. CNS Drugs 2005;19:709-16.
33. Egnell A, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharm Exp Ther 2003;305:1251-62.
34. Preskorn SH, Flockhart D. 2004 Guide to psychiatric drug interactions. Prim Psychiatry 2004;11:39-60.
35. Somerset Pharmaceuticals. Emsam (transdermal selegiline) package insert. Tampa, FL; 2006.
36. Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132.
37. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SG, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein. 2003;307:262-7.
38. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharm Ther 2004;76:192-200.
39. Artama M, Auvieen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use in women with epilepsy and congenital malformations in offspring. Neurology 2005;64:1874-8.
40. Wyszynski DF, Holmes LB. The AED (antiepileptic drug) pregnancy registry: a six-year experience [abstr]. Epilepsia 2004;45(suppl 3):56.
41. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005;4:781-6.
42. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
43. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001;158:1001-9.
44. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66:211-17.
45. Okuma T, Yamashita I, Takahasi R, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990;23: 143-50.
46. Ballenger J, Post R. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Psychopharmacology 1978;2:159-75.
47. Petit P, Lonjon R, Cociglio M, et al. Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates. Eur J Clin Pharmacol 1991;41: 541-6.
48. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasability, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 2000;150:15-23.
49. Brown D, Silverstone T, Cookson J. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 1989;4:229-38.
50. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987;48:89-93.
51. Hirschfeld RMA, Kasper S. A review of the evidence for carbamazepine and oxcarbamazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004;7:507-22.
52. Dardennes R, Even C, Bange F, Heim A. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta analysis. Br J Psychiatry 1995;166:378-81.
53. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981;73:95-6.
54. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 subjects. J Clin Psychiatry 1986;47:490-4.
55. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987;150:180-2.
56. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.
57. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915-21.
58. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-18.
59. Denicoff KD, Smith-Jackson EE, Disney ER, Omar Ali S, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-8.
60. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000;42(suppl 1):2-10.
61. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA, and the LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar subjects. J Clin Psychiatry 2003;64:144-51.
62. Kleindienst N, Greil W. Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychol Med 2002;32:493-501.
63. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997;43:151-61.
64. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in subjects with bipolar I disorder. Int Clin Psychopharmacol 1999;14:277-81.
65. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999;14:283-5.
66. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18:455-60.
67. Inoue K, Arima S, Tanaka K. A lithium and carbamazepine combination in the treatment of bipolar disorder: preliminary report. Folia Psychiatr Neurol Jpn 1981;35:465-75.
68. Nolen WA. Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. Acta Psychiatr Scand 1983;67:218-25.
69. Fawcett J, Kravitz HM. The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. J Clin Psychiatry 1985;46:58-60.
70. Shukia S, Cook BL, Miller MG. Lithium-carbamazepine vs. lithium-neuroleptic prophylaxis in bipolar illness. J Affect Disord 1985;9:219-22.
71. Lovett L, Watkins SE, Shaw DM. The use of alternative drug therapy in nine subjects with recurrent affective disorder resistant to conventional prophylaxis. Biol Psychiatry 1986;21:1344-7.
72. Post RM, Leverich GL, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990;10:318-27.
73. Strömgren LS. The combination of lithium and carbamazeplne in treatment and prevention of manic-depressive disorder: review and case report. Compr Psychiatry 1990;31:261-5.
74. DiCostanza E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar disorder. Acta Psychiatr Scand 1991;83:456-9.
75. Kishimoto A. The treatment of affective disorder with carbamazepine: prophylactic synergism of lithium and carbamazepine combination. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:483-93.
76. Fritze J, Beneke M, Lanczik M, et al. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders. Pharmacopsychiatry 1994;27:181-5.
77. Peselow ED, Fieve RR, DiFiglia C, Sanfilipo MP. Lithium prophylaxis of bipolar illness: value of combination treatment. Br J Psychiatry 1994;164:208-14.
78. Bocchetta A, Chillotti C, Severino G, Ardau R, Del Zompo M. Carbamazepine augmentation in lithium-refractory bipolar subjects: a prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 1997;17:92-6.
79. Baethge C, Baldessarini RJ, Mathiske-Schmidt K, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar 1 subjects. J Clin Psychiatry 2005;66:174-82.
80. Tonda L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003;108:4-14.
81. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid-cycling affective disorder: contributing factors and treatment responses in 51 subjects. Am J Psychiatry 1988;145:179-84.
82. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993;27:138-45.
83. Fujiwara Y, Honda T, Tanaka Y, Aoki S, Kuroda S. Comparison of early- and late-onset rapid cycling affective disorders: clinical course and response to pharmacotherapy. J Clin Psychopharmacol 1998;18:282-8.
84. Suppes T, Rush JA, Dennehy EB, et al. Texas medication algorithm project, phase 3 (TMAP-3): clinical results for subjects with a history of mania. J Clin Psychiatry 2003;64: 370-82.
85. Weisler RH, Kalali AH, Ketter TA, et al. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as mono-therapy for bipolar disorder subjects with manic or mixed episodes. J Clin Psychiatry 2004;65:478-84.
86. Weisler RH, Keck PE, Swann AC, Cutler AJ, Ketter TA, Kalali AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005;66:323-30. (Erratum in J Clin Psychiatry 2005;66:659.)
87. Ketter TA, Kalali AH, Weisler RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder subjects with manic or mixed episodes. J Clin Psychiatry 2004;65:668-73.